Lista de obras -

31-year-old woman with confusion and labile behavior

artículo científico publicado en 2002

A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer ⬇️

artículo científico publicado el 1 de febrero de 2012

A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients

artículo científico publicado en 2019

A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Canc

scientific article published on 09 October 2019

A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326.

artículo científico publicado en 2010

A multidisciplinary approach to the management of breast cancer, part 1: prevention and diagnosis

artículo científico publicado en 2007

A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations

artículo científico publicado en 2007

A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer

artículo científico publicado en 2005

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors

artículo científico publicado en 2016

A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors

scientific article published on 24 April 2020

A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors

artículo científico publicado en 2014

A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.

artículo científico publicado en 2003

A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies

artículo científico publicado en 2013

A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer

artículo científico publicado en 2005

A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.

artículo científico publicado en 2005

A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies

artículo científico publicado en 2013

A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer

artículo científico publicado en 2013

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced

artículo científico publicado en 2017

A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors

artículo científico publicado en 2005

A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.

artículo científico publicado en 2005

A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528

artículo científico publicado en 2013

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

artículo científico publicado en 2015

Advances in Cancer Immunotherapy in Solid Tumors

artículo científico publicado en 2016

Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options

artículo científico publicado en 2016

Angiogenesis inhibitors in lung cancer: a promise fulfilled

artículo científico publicado en 2006

BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins

artículo científico publicado en 2008

Body Mass Index Influences the Salutary Effects of Metformin on Survival After Lobectomy for Stage I NSCLC

artículo científico publicado en 2019

Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study.

artículo científico publicado en 2012

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature

article

Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database.

artículo científico publicado en 2017

Complementary and alternative medicine use among patients with thoracic malignancies

artículo científico publicado en 2014

Complementary and alternative medicine use by patients enrolled onto phase I clinical trials

artículo científico publicado en 2004

Concomitant Mediastinoscopy Increases the Risk of Postoperative Pneumonia After Pulmonary Lobectomy.

artículo científico publicado en 2018

Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.

artículo científico publicado en 2010

Critical acral ischaemia leading to multiple finger amputation: side-effect of long-term (>30 cycles) pemetrexed maintenance treatment in a patient

artículo científico publicado en 2014

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC

artículo científico publicado en 2018

Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo

artículo científico publicado en 2011

Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review

artículo científico publicado en 2014

Effect of the number of lymph nodes examined on the survival of patients with stage I non-small cell lung cancer who undergo sublobar resection

artículo científico publicado en 2018

Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung Cancer

artículo científico publicado en 2020

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer

artículo científico publicado en 2020

Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways

artículo científico publicado en 2016

Emerging therapeutic targets in non-small cell lung cancer

artículo científico publicado en 2009

Farnesyl transferase inhibitors as anticancer agents

artículo científico publicado en 2002

Farnesyltransferase inhibitors in breast cancer therapy

artículo científico publicado en 2002

First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel

scientific article published on 24 December 2013

First-line cytotoxic chemotherapy regimen for non-small cell lung cancer in the elderly population: plus ça change

scientific article published on 01 August 2020

First-line treatment of advanced ALK-positive non-small-cell lung cancer

artículo científico publicado en 2015

Identification and characterization of genetic variation in the folylpolyglutamate synthase gene

scientific article published on 01 September 2007

Identification of Epidermal Growth Factor Receptor Tyrosine-Kinase Mutations in Non-small Cell Lung Cancer: Testing Platform Matters

scientific article published on 18 March 2020

Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.

artículo científico publicado en 2007

Improved Response to nab-Paclitaxel Compared with Cremophor-Solubilized Paclitaxel is Independent of Secreted Protein Acidic and Rich in Cysteine Expression in Non-Small Cell Lung Cancer ⬇️

artículo científico publicado el 1 de junio de 2011

Investigational agents in metastatic basal cell carcinoma: focus on vismodegib

artículo científico publicado en 2012

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

scientific article published on 20 September 2020

Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144.

artículo científico publicado en 2009

MEK/MAPK inhibitors ⬇️

artículo científico publicado el 1 de diciembre de 2010

Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer

artículo científico publicado en 2013

NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status

artículo científico publicado en 2014

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

scholarly article by Jeffrey M Conroy et al published 24 January 2019 in Journal for Immunotherapy of Cancer

Novel pharmacological agents in clinical development for solid tumours

artículo científico publicado en 2001

Novel targets for lung cancer therapy: part I.

artículo científico publicado en 2002

Novel targets for lung cancer therapy: part II.

artículo científico publicado en 2002

Novel taxanes/epothilones ⬇️

artículo científico publicado el 1 de diciembre de 2010

Obstacles and opportunities in the clinical development of targeted therapeutics.

artículo científico publicado en 2005

Oncologist uptake of comprehensive genomic profile guided targeted therapy

scientific article published on 23 July 2019

P2.36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets): Track: Immunotherapy

artículo científico publicado en 2016

Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors ⬇️

artículo científico publicado el 13 de julio de 2011

Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors

artículo científico publicado en 2014

Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumors

artículo científico publicado en 2015

Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer ⬇️

artículo científico publicado el 14 de febrero de 2012

Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies

artículo científico publicado en 2017

Phase II Trial of Sunitinib Maintenance Therapy After Platinum-Based Chemotherapy in Patients with Extensive-Stage Small Cell Lung Cancer ⬇️

artículo científico publicado el 1 de junio de 2011

Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in non-small-cell lung cancer

artículo científico publicado en 2014

Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.

artículo científico publicado en 2009

Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.

artículo científico publicado en 2012

Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.

artículo científico publicado en 2012

Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer

scientific article published on 27 April 2018

Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage

scientific article published on 01 October 2004

Pneumonectomy-Sparing NSAID Therapy for Pulmonary Inflammatory Myofibroblastic Tumor.

artículo científico publicado en 2015

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients

scholarly article by Sarabjot Pabla et al published 1 February 2019 in Journal for Immunotherapy of Cancer

Promoting cancer control training in resource limited environments: Lagos, Nigeria

artículo científico publicado en 2014

Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events

artículo científico publicado en 2017

Risk and benefit of neoadjuvant therapy among patients undergoing resection for non-small-cell lung cancer

artículo científico publicado en 2017

Role of Private Enterprise in Cancer Control in Low to Middle Income Countries

artículo científico publicado en 2016

SRC inhibitors

scientific article published on 01 December 2010

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study

artículo científico publicado en 2015

Safety of Same-Day Vitamin B12 Supplementation in Patients Receiving Pemetrexed for the Treatment of Non-Small-Cell Lung Cancer or Pleural Mesothelioma: A Retrospective Analysis

artículo científico publicado en 2018

Sensitive Detection of Exosomal Proteins via a Compact Surface Plasmon Resonance Biosensor for Cancer Diagnosis

artículo científico publicado en 2018

Small Cell Lung Cancer

scientific article published on 01 March 2008

Systemic cancer therapy: evolution over the last 60 years

artículo científico publicado en 2008

The case of the slandered Halloween cupcake: survival after massive pediatric procainamide overdose

artículo científico publicado en 2002

The prognostic significance of focal adhesion kinase expression in stage I non-small-cell lung cancer

artículo científico publicado en 2014

The role of farnesyltransferase inhibitors in lung cancer therapy

artículo científico publicado en 2002

The role of focal adhesion kinase in lung cancer

artículo científico

Thoracoscopic organ suffusion for regional lung chemotherapy (preliminary results).

artículo científico publicado en 2009

Topotecan and paclitaxel in previously treated patients with relapsed small cell lung cancer: phase II trial of the North Central Cancer Treatment Group

artículo científico publicado en 2006

Transcervical Extended Mediastinal Lymphadenectomy: Experience From a North American Cancer Center

artículo científico publicado en 2017

Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing

Understanding, recognizing, and managing toxicities of targeted anticancer therapies

artículo científico publicado en 2013

Vitamin D3 Metabolites Demonstrate Prognostic Value in EGFR-Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance

scientific article published on 13 March 2020

Lista de obras de

31-year-old woman with confusion and labile behavior

A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer ⬇️

A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients

A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Canc

A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326.

A multidisciplinary approach to the management of breast cancer, part 1: prevention and diagnosis

A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations

A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors

A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors

A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors

A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.

A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies

A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer

A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.

A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies

A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced

A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors

A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.

A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Advances in Cancer Immunotherapy in Solid Tumors

Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options

Angiogenesis inhibitors in lung cancer: a promise fulfilled

BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins

Body Mass Index Influences the Salutary Effects of Metformin on Survival After Lobectomy for Stage I NSCLC

Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study.

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature

Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database.

Complementary and alternative medicine use among patients with thoracic malignancies

Complementary and alternative medicine use by patients enrolled onto phase I clinical trials

Concomitant Mediastinoscopy Increases the Risk of Postoperative Pneumonia After Pulmonary Lobectomy.

Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.

Critical acral ischaemia leading to multiple finger amputation: side-effect of long-term (>30 cycles) pemetrexed maintenance treatment in a patient

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC

Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo

Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review

Effect of the number of lymph nodes examined on the survival of patients with stage I non-small cell lung cancer who undergo sublobar resection

Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung Cancer

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer

Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways

Emerging therapeutic targets in non-small cell lung cancer

Farnesyl transferase inhibitors as anticancer agents

Farnesyltransferase inhibitors in breast cancer therapy

First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel

First-line cytotoxic chemotherapy regimen for non-small cell lung cancer in the elderly population: plus ça change

First-line treatment of advanced ALK-positive non-small-cell lung cancer

Identification and characterization of genetic variation in the folylpolyglutamate synthase gene

Identification of Epidermal Growth Factor Receptor Tyrosine-Kinase Mutations in Non-small Cell Lung Cancer: Testing Platform Matters

Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.

Improved Response to nab-Paclitaxel Compared with Cremophor-Solubilized Paclitaxel is Independent of Secreted Protein Acidic and Rich in Cysteine Expression in Non-Small Cell Lung Cancer ⬇️

Investigational agents in metastatic basal cell carcinoma: focus on vismodegib

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144.

MEK/MAPK inhibitors ⬇️

Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer

NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

Novel pharmacological agents in clinical development for solid tumours

Novel targets for lung cancer therapy: part I.

Novel targets for lung cancer therapy: part II.

Novel taxanes/epothilones ⬇️

Obstacles and opportunities in the clinical development of targeted therapeutics.

Oncologist uptake of comprehensive genomic profile guided targeted therapy

P2.36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets): Track: Immunotherapy

Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors ⬇️

Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors

Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumors

Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer ⬇️

Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies

Phase II Trial of Sunitinib Maintenance Therapy After Platinum-Based Chemotherapy in Patients with Extensive-Stage Small Cell Lung Cancer ⬇️

Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in non-small-cell lung cancer

Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.

Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.

Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.

Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer

Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage

Pneumonectomy-Sparing NSAID Therapy for Pulmonary Inflammatory Myofibroblastic Tumor.